Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc (JAZZ) director Norbert G. Riedel reported dispositions of Ordinary Shares on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 shares were delivered or withheld for taxes, and an entity-related trust holds 10,630 Ordinary Shares indirectly after the reported transactions. No Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc director Ted W. Love reported dispositions of 743 Ordinary Shares on August 31, 2026. Two separate share withholdings of 6 and 737 shares were used to pay tax obligations triggered by the vesting of previously granted restricted stock units. These were administrative tax-withholding events, not open-market sales, and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) reported insider activity by director Laura Hamill involving dispositions of ordinary shares on August 31, 2026. Two transactions totaling 1,706 shares were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units, rather than open-market sales. No Rule 10b5-1 trading plan is reported for these transactions.
Jazz Pharmaceuticals plc (JAZZ) reported that director Jennifer E. Cook disposed of ordinary shares on August 31, 2026 to satisfy tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 ordinary shares were delivered or withheld for tax, in two transactions priced at $244.0643 and $241.39 per share, respectively. No Rule 10b5-1 trading plan is reported in connection with these transactions.
Jazz Pharmaceuticals plc (JAZZ) director Patrick G. Enright reported two dispositions of ordinary shares on August 31, 2026, when 14 shares at $244.64 and 1,692 shares at $241.39 were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units; these were not open-market sales and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) director Heather Ann McSharry reported two dispositions of Ordinary Shares on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,855 shares were delivered or withheld for tax payment, and no Rule 10b5-1 plan is reported.
Jazz Pharmaceuticals plc (JAZZ) reported that director Patrick Kennedy disposed of shares in connection with equity compensation on August 31, 2026. Two transactions used a total of 1,855 Ordinary Shares to pay tax obligations arising from the vesting of previously granted restricted stock units, with no open-market purchases or sales reported and no Rule 10b5-1 trading plan indicated.
Jazz Pharmaceuticals plc (JAZZ) reported that director Rick E. Winningham had a total of 1,706 Ordinary Shares delivered or withheld on August 31, 2026 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. These dispositions were not open-market sales and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported selling 6,000 Ordinary Shares of JAZZ on September 1, 2026 at $250.13 per share in an open-market or private transaction. On August 31, 2026, he also disposed of 1,219 shares to pay tax liabilities from vesting restricted stock units, including a previously unreported 3,193-share tax withholding from November 3, 2025. The September 1, 2026 sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2025.
Jazz Pharmaceuticals plc (JAZZ) officer Bruce C. Cozadd filed a Rule 144 notice for a planned sale of 6,000 shares of common stock through Merrill Lynch, with an aggregate market value of $1,500,780, expected on September 1, 2026 on NASDAQ.
The filing also lists prior open-market sales of 6,000 shares each on June 1, July 1, and August 3, 2026.